These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19450103)

  • 21. Pharmaceutical industry financial performance.
    Goodman M
    Nat Rev Drug Discov; 2009 Dec; 8(12):927-8. PubMed ID: 19949398
    [No Abstract]   [Full Text] [Related]  

  • 22. Making or losing money with participation in clinical trials: a decision analysis.
    Jacobs VR
    Onkologie; 2009 Jul; 32(7):411-6. PubMed ID: 19556819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding and evaluating original research articles.
    Motheral BR; Jackson TR
    J Am Pharm Assoc (Wash); 1999; 39(6):759-74; quiz 871-3. PubMed ID: 10609441
    [No Abstract]   [Full Text] [Related]  

  • 24. Economic lessons in the land of plenty.
    Pontious JM
    J Okla State Med Assoc; 2013 Apr; 106(4):123-4. PubMed ID: 23795522
    [No Abstract]   [Full Text] [Related]  

  • 25. Early stopping for benefit in National Cancer Institute-sponsored randomized Phase III trials: the system is working.
    Sargent D
    J Clin Oncol; 2009 Apr; 27(10):1543-4. PubMed ID: 19237627
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative effectiveness research in oncology: the need for clarity, transparency and vision.
    Lyman GH
    Cancer Invest; 2009 Jul; 27(6):593-7. PubMed ID: 19557579
    [No Abstract]   [Full Text] [Related]  

  • 27. [Factors in expenditures for pharmaceuticals].
    PEQUIGNOT H; ROSCH G; VESSEREAU A
    Sem Med Prof Med Soc; 1959 Aug; 35():783-4. PubMed ID: 14431691
    [No Abstract]   [Full Text] [Related]  

  • 28. [Health expenses and medical practice].
    Do JP; Sérange R
    Lyon Med; 1972 Apr; 19():Suppl:63-6. PubMed ID: 4641439
    [No Abstract]   [Full Text] [Related]  

  • 29. [Health economic consequences of follicle stimulating hormone use].
    Ingerslev HJ
    Ugeskr Laeger; 2007 May; 169(20):1932; author reply 1932. PubMed ID: 17566242
    [No Abstract]   [Full Text] [Related]  

  • 30. Considering race/ethnicity and socio-economic status in randomized controlled trials. A commentary on Frampton et al.'s systematic review generalizing trial findings and tackling health disparities in asthma research.
    Kreatsoulas C; Anand S
    Soc Sci Med; 2009 Oct; 69(8):1155-6. PubMed ID: 19640625
    [No Abstract]   [Full Text] [Related]  

  • 31. Health economic evaluation: in need of more analytical rigor or more practical relevance?
    Rovithis D
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):107-10. PubMed ID: 19402796
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of cluster-randomized trials on maternal and child health research in developing countries.
    Handlos LN; Chakraborty H; Sen PK
    Trop Med Int Health; 2009 Aug; 14(8):947-56. PubMed ID: 19563429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upping recruitment in clinical trials: are the costs worth it?
    McKoy JM; Samaras AT; Luu TH; Bennett CL
    Onkologie; 2009 Jul; 32(7):378-9. PubMed ID: 19556813
    [No Abstract]   [Full Text] [Related]  

  • 34. Generalisation from phase III clinical trials: survival, quality of life, and health economics.
    Fayers PM; Hand DJ
    Lancet; 1997 Oct; 350(9083):1025-7. PubMed ID: 9329528
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems.
    Westerlund T; Marklund B
    J Clin Pharm Ther; 2009 Jun; 34(3):319-27. PubMed ID: 19646078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of periodontal therapy on general health--is there a missing component in the design of these clinical trials?
    Armitage GC
    J Clin Periodontol; 2008 Dec; 35(12):1011-2. PubMed ID: 19040576
    [No Abstract]   [Full Text] [Related]  

  • 37. [Estimate of the sample size in economic evaluations of drugs].
    Soto J
    Med Clin (Barc); 1999 Jun; 112(20):797. PubMed ID: 10422064
    [No Abstract]   [Full Text] [Related]  

  • 38. A marriage of convenience.
    Nat Med; 2012 Apr; 18(4):469-70. PubMed ID: 22481385
    [No Abstract]   [Full Text] [Related]  

  • 39. [Important to keep the principle of value-based pricing of drugs].
    Persson U; Levin LA; Pettersson B
    Lakartidningen; 2009 Oct 28-Nov 3; 106(44):2862-4. PubMed ID: 19967967
    [No Abstract]   [Full Text] [Related]  

  • 40. Are the economics of complementary and alternative medicine different to conventional medicine?
    Spinks J; Hollingsworth B
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):1-4. PubMed ID: 19371170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.